Bio-Techne (TECH) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09073M1045

(NASDAQ:TECH Stock) Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota. Web URL: https://www.bio-techne.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Bio-Techne (TECH) - Stock Price & Dividends

TECH Stock Overview

Market Cap in USD 10,614m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Life Sciences Tools & Services
TER 0.00%
IPO / Inception 1989-02-09

TECH Stock Ratings

Fundamental 4.90
Dividend 5.00
Growth 5y 2.11
Rel. Performance vs Sector -1.67
Analysts 4.67
Fair Price Total Ret. 66.80
Fair Price DCF 38.53

TECH Dividends

Yield 12m 0.45%
Yield on Cost 5y 0.67%
Dividends CAGR 5y 0.00%
Payout Consistency 96.0%

TECH Growth Ratios

Growth 12m -2.96%
Growth Correlation 12m -33%
Growth Correlation 3m 10%
CAGR 5y 8.57%
CAGR / Mean Drawdown 0.44
Sharpe Ratio 12m -0.25
Alpha vs SP500 12m -29.74
Beta vs SP500 5y weekly 1.01
CAPM 8.02%
Average Daily Range 2m 2.92%
Regime Oscillator 73.88
Volatility GJR Garch 1y 37.24%
Price / SMA 50 -0.38%
Price / SMA 200 -2.44%
Current Volume 1373.9k
Average Volume 20d 1169.5k

External Links for TECH Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of TECH stocks?
As of February 22, 2024, the stock is trading at USD 71.72 with a total of 1,373,852 shares traded.
Over the past week, the price has changed by +2.28%, over one month by -0.30%, over three months by +13.04% and over the past year by -2.20%.
Why is TECH stock down?
Check with which Index or Commodity TECH has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return TECH Return S&P 500
1 Month -0.30% 2.85%
3 Months 13.04% 10.14%
12 Months -2.20% 26.48%
What is the forecast for TECH stock price target?
According to ValueRays Forecast Model, TECH Bio-Techne will be worth about 73.1 in February 2025. The stock is currently trading at 71.72. This means that the stock has a potential upside of +1.91%.
Issuer Forecast Upside
Wallstreet Target Price 80.4 12.1%
Analysts Target Price 101 40.8%
ValueRay Target Price 73.1 1.9%